Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR EBITDA Margin

EBITDA as a percentage of revenue.

Champions Oncology, Inc.NASDAQ: CSBR

EBITDA Margin · Q3 FY2026 · quarter ended Jan 2026

EBITDA Margin narrows to 0.6%

EBITDA Margin was 0.6% in Q3 FY2026, down 28.2 pp from a year earlier. On a trailing-twelve-month basis it was -1.6%, down 16.1 pp year over year. Over 3 fiscal years it widened by 6.5 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 5.9% for the fiscal year ending Apr 2026, down from 11.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
0.6%-3.4 pp QoQ
Last fiscal yearApr 2025
11.0%+21.9 pp YoY
LTMJan 2026
-1.6%-16.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-28.2 pp+9.8 pp+38.0 pp
1 year+21.9 pp-5.1 pp-26.9 pp
3 years+6.5 pp——
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
11.0%
Year-over-year change
+21.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CSBR compares with its peers on the latest reported figures

  • CSBR's LTM Jan 2026 EBITDA Margin of -1.6% is the 2nd highest of the 8 companies compared; the peer median is -4623.1%.
  • Its year-over-year change of -16.1 pp is the 2nd highest of 7, against a peer median of -3877.4 pp.
  • Over three fiscal years its change of +6.5 pp compares with a peer median of +381.6 pp.
CSBR Competitors Peer median
EBITDA Margin for CSBR and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253772.2% —+5140.2 pp
CSBRChampions Oncology, Inc.LTM Jan 2026-1.6% -16.1 pp+6.5 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-23.7% -20.8 pp+381.6 pp
STROSutro Biopharma, Inc.LTM Mar 2026-106.5% +169.1 pp+12.9 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4623.1% -3172.4 pp+10652.3 pp
IMAImageneBio IncFY2025-5583.3% -4582.4 pp-5147.8 pp
CNTBConnect Biopharma Holdings LimitedFY2025-85279.7% -85223.0 pp—
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
Peer median (excluding CSBR) -4623.1%-3877.4 pp+381.6 pp

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.